12:00 AM
 | 
Feb 25, 2013
 |  BC Week In Review  |  Company News  |  Deals

Caliber Biotherapeutics, iBio deal

iBio granted Caliber a non-exclusive license to use iBio's iBioLaunch plant-based vaccine and therapeutic protein manufacturing platform to develop and commercialize biopharmaceuticals against targets provided by Caliber....

Read the full 115 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >